Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Eton Pharmaceuticals (NASDAQ: ETON), a pharmaceutical company specializing in rare disease treatments, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025. The company will host a conference call and audio webcast at 4:30 p.m. ET (3:30 p.m. CT) to discuss the results.
Management will take live questions during the call and will also address emailed questions from investors sent to [email protected]. The webcast will be accessible through Eton's investor relations website and will remain available for 30 days after the event.
Eton Pharmaceuticals (NASDAQ: ETON), un'azienda farmaceutica specializzata in trattamenti per malattie rare, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per marted矛 13 maggio 2025. La societ脿 terr脿 una conference call e una trasmissione audio in webcast alle 16:30 ET (15:30 CT) per discutere i risultati.
Il management risponder脿 a domande in diretta durante la chiamata e affronter脿 anche le domande inviate via email dagli investitori all'indirizzo [email protected]. Il webcast sar脿 accessibile tramite il sito web delle relazioni con gli investitori di Eton e rester脿 disponibile per 30 giorni dopo l'evento.
Eton Pharmaceuticals (NASDAQ: ETON), una compa帽铆a farmac茅utica especializada en tratamientos para enfermedades raras, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el martes 13 de mayo de 2025. La empresa realizar谩 una llamada en conferencia y una transmisi贸n de audio por webcast a las 4:30 p.m. ET (3:30 p.m. CT) para discutir los resultados.
La direcci贸n responder谩 preguntas en vivo durante la llamada y tambi茅n atender谩 preguntas enviadas por correo electr贸nico por los inversores a [email protected]. El webcast estar谩 disponible a trav茅s del sitio web de relaciones con inversores de Eton y permanecer谩 accesible durante 30 d铆as despu茅s del evento.
Eton Pharmaceuticals (NASDAQ: ETON)電� 頋穩 歆堩櫂 旃橂鞐� 韸鬼檾霅� 鞝滌暯 須岇偓搿�, 2025雲� 1攵勱赴 鞛 鞁れ爜 氚滍憸毳� 2025雲� 5鞗� 13鞚� 頇旍殧鞚�鞐� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟. 須岇偓電� 鞓ろ泟 4鞁� 30攵� ET (鞓ろ泟 3鞁� 30攵� CT)鞐� 旎嵓霟办姢 旖滉臣 鞓る敂鞓� 鞗轨簮鞀ろ姼毳� 韱淀暣 鞁れ爜鞚� 雲检潣頃� 鞓堨爼鞛呺媹雼�.
瓴届榿歆勳潃 韱淀檾 欷� 鞁れ嫓臧� 歆堧鞚� 氚涥碃, 韴瀽鞛愲摛鞚� [email protected]鞙茧 氤措偢 鞚措⿺鞚� 歆堧霃� 雼惦硛頃� 鞓堨爼鞛呺媹雼�. 鞗轨簮鞀ろ姼電� Eton鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐愳劀 鞝戩啀 臧�電ロ晿氅�, 頄夓偓 頉� 30鞚缄皠 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
Eton Pharmaceuticals (NASDAQ : ETON), une soci茅t茅 pharmaceutique sp茅cialis茅e dans les traitements des maladies rares, a programm茅 l'annonce de ses r茅sultats financiers du premier trimestre 2025 pour le mardi 13 mai 2025. L'entreprise organisera une conf茅rence t茅l茅phonique et une diffusion audio en webcast 脿 16h30 ET (15h30 CT) pour discuter des r茅sultats.
La direction r茅pondra aux questions en direct pendant l'appel et prendra 茅galement en compte les questions envoy茅es par e-mail par les investisseurs 脿 [email protected]. Le webcast sera accessible via le site des relations investisseurs d'Eton et restera disponible pendant 30 jours apr猫s l'茅v茅nement.
Eton Pharmaceuticals (NASDAQ: ETON), ein Pharmaunternehmen, das sich auf die Behandlung seltener Krankheiten spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse f眉r das erste Quartal 2025 f眉r Dienstag, den 13. Mai 2025 geplant. Das Unternehmen wird eine Telefonkonferenz und eine Audio-Webcast um 16:30 Uhr ET (15:30 Uhr CT) abhalten, um die Ergebnisse zu besprechen.
Das Management wird w盲hrend des Anrufs live Fragen beantworten und auch per E-Mail an [email protected] eingereichte Fragen von Investoren behandeln. Der Webcast wird 眉ber die Investor-Relations-Website von Eton zug盲nglich sein und f眉r 30 Tage nach der Veranstaltung verf眉gbar bleiben.
- None.
- None.
DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (鈥淓ton鈥� or the 鈥淐ompany鈥�) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2025 financial results on Tuesday, May 13, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
Dial In* (Audio Only)聽 聽 聽 聽聽
Webcast:聽 聽 聽 聽 聽 聽 聽 聽 聽 聽 聽 聽 聽聽
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: .
The live webcast can also be accessed on the Investors section of Eton鈥檚 website at . An archived webcast will be available on Eton鈥檚 website approximately two hours after the completion of the event and for 30 days thereafter.
*Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX庐, ALKINDI SPRINKLE庐, GALZIN庐, PKU GOLIKE庐, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia庐, ET-700, ET-800 and ZENEO庐 hydrocortisone autoinjector. For more information, please visit our website at .
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E:
Source: Eton Pharmaceuticals, Inc.
FAQ
When will Eton Pharmaceuticals (ETON) report Q1 2025 earnings?
How can investors participate in Eton Pharmaceuticals' Q1 2025 earnings call?
Where can I access the replay of Eton Pharmaceuticals' Q1 2025 earnings webcast?
What is Eton Pharmaceuticals' main business focus?
